Sarepta's 'Unprecedented Times' Continue As Company Rebukes The FDA – Investor's Business Daily

Business News

  1. Sarepta’s ‘Unprecedented Times’ Continue As Company Rebukes The FDA  Investor’s Business Daily
  2. We are mothers of Duchenne patients. Recent setbacks with Sarepta must not stop progress  statnews.com
  3. Drugmaker Refuses F.D.A. Request to Pull Treatment Linked to Patient Deaths  The New York Times
  4. Sarepta Therapeutics stock sinks after FDA tells company to stop shipping its bestselling drug  Yahoo Finance
  5. Sarepta LGMD trials all hit by FDA hold amid newly surfaced safety concerns over gene therapy  Fierce Biotech

Source: Business News

/by